A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity Index (PASI) and Investigator’s Global Assessment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of pharmacokinetics and pharmacodynamics 2018-08, Vol.45 (4), p.523-535
Hauptverfasser:	Hu, Chuanpu, Yao, Zhenling, Chen, Yang, Randazzo, Bruce, Zhang, Liping, Xu, Zhenhua, Sharma, Amarnath, Zhou, Honghui
Format:	Artikel
Sprache:	eng
Schlagworte:	Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Body weight Clinical trials Data processing Evaluation Exposure Immunoglobulin A Immunoglobulin G Interleukin 23 Monoclonal antibodies Original Paper Pharmacokinetics Pharmacology/Toxicology Pharmacy Placebo effect Placebos Psoriasis Veterinary Medicine/Veterinary Science
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!